New tests planned after Parkinson's drug fails trial

Merck KGaA and its development partner, Newron, say that a late-stage study of their experimental therapy for Parkinson's failed to demonstrate any significant effect. But the two developers refuse to walk away from safinamide. Researchers are planning to mount new trials with lower doses to find the right formula.

"The primary endpoint, time to intervention, did not reach statistical significance when data from both safinamide dose groups were pooled," the companies said, after reviewing 18 months of combined data from patients taking the 50-100 mg and 120-200 mg doses. But researchers said that a lack of response among patients taking the highest dose could have skewed the data. Adding safinamide to dopamine agonist therapy at 50-100 mg daily could delay the time to therapeutic adjustment.

- see the release on the trial data
- read the AFX report

Related Articles:
Italy's Newron gains $99 million in IPO. Report
Newron launches a Phase III trial on eve of IPO. Report
Serono licenses Newron Parkinson's therapy. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.